Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-314 in Hospitalized COVID-19 Pneumonia
NCT04871646Phase 3
Key facts
- Status
- Unknown
- Start
- Jun 2021
- Primary completion
- Mar 2022
- Countries
- 1
- Sponsor
- Chong Kun Dang Holdings
- Modality
- Small Molecules
- Drugs
- Nafabelltan
- Conditions
- COVID-19 pneumonia
01
Overview
Phase 3, randomised, double-blind trial in COVID-19 pneumonia comparing CKD-314 + SOC with Placebo + SOC (2 arms). Primary endpoint: Time to Recovery at 28 days. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
CKD-314 + SOC
Intravenous CKD-314 + Standard of Care
Placebo + SOC
Intravenous Placebo + Standard of Care
03
Who it enrols
Adult patients (≥18 years) hospitalized with confirmed COVID-19 infection and pneumonia who can provide informed consent.
04
Endpoints
Primary
Time to Recovery
Secondary
Time to Clinical Improvement
Beyond the preview
Go deeper on NCT04871646.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871646.